Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist1.

After nearly 20 years of infection control, documented long-term in vitro potency with ZYVOX continues2

Consideration should be given to official guidance on the appropriate use of antibacterial agents. 

Full preview

Adapted from Mendes RE, et al. J Antimicrob Chemother. 2018.

AMR, antimicrobial resistance; E. faecium, Enterococcus faecium; E.faecalis, Enterococcus faecalis; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; S.pneumoniae, Streptococcus pneumoniae


  1. ZYVOX® Summary of Product Characteristics
  2. Mendes RE, et al. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. J Antimicrob Chemother. 2018; 73(7): 1880-1887